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MaBACKGROUND Mild hypertrophy but increased arrhythmic risk characterizes the stereotypic phenotype proposed for
hypertrophic cardiomyopathy (HCM) caused by thin-ﬁlament mutations. However, whether such clinical proﬁle is
different from more prevalent thick-ﬁlament–associated disease is unresolved.
OBJECTIVES This study aimed to assess clinical features and outcomes in a large cohort of patients with HCM
associated with thin-ﬁlament mutations compared with thick-ﬁlament HCM.
METHODS Adult HCM patients (age >18 years), 80 with thin-ﬁlament and 150 with thick-ﬁlament mutations, were
followed for an average of 4.5 years.
RESULTS Compared with thick-ﬁlament HCM, patients with thin-ﬁlament mutations showed: 1) milder and atypically
distributed left ventricular (LV) hypertrophy (maximal wall thickness 18  5 mm vs. 24  6 mm; p < 0.001) and less
prevalent outﬂow tract obstruction (19% vs. 34%; p ¼ 0.015); 2) higher rate of progression to New York Heart Asso-
ciation functional class III or IV (15% vs. 5%; p ¼ 0.013); 3) higher prevalence of systolic dysfunction or restrictive
LV ﬁlling at last evaluation (20% vs. 9%; p ¼ 0.038); 4) 2.4-fold increase in prevalence of triphasic LV ﬁlling pattern
(26% vs. 11%; p¼ 0.002); and 5) similar rates of malignant ventricular arrhythmias and sudden cardiac death (p¼ 0.593).
CONCLUSIONS In adult HCM patients, thin-ﬁlament mutations are associated with increased likelihood of advanced
LV dysfunction and heart failure compared with thick-ﬁlament disease, whereas arrhythmic risk in both subsets is
comparable. Triphasic LV ﬁlling is particularly common in thin-ﬁlament HCM, reﬂecting profound diastolic
dysfunction. (J Am Coll Cardiol 2014;64:2589–600) © 2014 by the American College of Cardiology Foundation.
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FIGURE 1 The Cardiac Sarcomere Thin Filament
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2590The thin ﬁlament is a multisubunit, al-
losterically regulated molecular machine
(Figure 1); thus, mutations in any of its compo-
nents should exert similar biophysical effects
and pathophysiological consequences (4,6).
However, a comprehensive assessment of the
clinical presentation and outcome of patients
carrying thin-ﬁlament mutations, compared
with thick-ﬁlament disease, has not yet been
performed. Initial clinical phenotype de-
scriptions of TNNT2 and TNNI3mutations were
fromfamilieswithsevereHCM,characterizedby
high incidence of sudden cardiac death (SCD)
despite relatively mild hypertrophy, often in
children and adolescents (7–10). IdentiﬁcationSEE PAGE 2601Schematic representation of the thin ﬁlament and its key molec-
ular components (colored) in relation to thick-ﬁlament proteins
(gray). Thin-ﬁlament proteins with disease-causing mutations
found in the thin-ﬁlament cohort of this study are circled in red.of mutations in these genes is therefore poten-
tially relevant to clinical decision-making,
including risk stratiﬁcation for arrhythmic pro-
phylaxis. However, subsequent reports of
larger, less-selected cohorts show wide pheno-
typic and clinical variability for individual thin-
ﬁlament genes, similar to thick-ﬁlament HCM
(5,11,12). Consequently, whether thin-ﬁlament
HCM has a truly distinct clinical proﬁle from
thick-ﬁlament HCM is unresolved. This study
speciﬁcally addressed this issue by evaluating
the clinical spectrum, echocardiographic fea-
tures, and outcomes of a large, multicenter,
genotyped cohort with HCM.METHODS
PATIENT POPULATION. All participants were un-
related index patients. HCM diagnosis was by
2-dimensional echocardiographic identiﬁcation of a
hypertrophied ($13 mm), nondilated LV, in the ab-
sence of another cardiac or systemic disease capable
of producing that magnitude of ventricular hyper-
trophy (13). The study included 80 HCM patients
(8% of HCM patients genotyped during this time)
with a pathogenic or likely pathogenic cardiac thin-
ﬁlament gene mutation identiﬁed between January
2001 and December 2009 at 4 referral centers: Careggi
University Hospital, Florence, Italy; Brigham and
Women’s Hospital, Boston, Massachusetts; Stanford
Medical Center, Palo Alto, California, and the Uni-
versity of Michigan Medical Center, Ann Arbor,
Michigan (Table 1).
For comparison, we evaluated 150 HCM patients
with pathogenic or likely pathogenic mutations in the
cardiac thick-ﬁlament genes MYH7 and MYBPC3 and
the regulatory light chain (MYL2) consecutivelyidentiﬁed in Florence during the same period. Clinical
features of this reference group (Table 1) closely
recapitulate published HCM cohorts from Europe and
the United States (14–16), largely comprising thick-
ﬁlament patients. Previous collaborative studies
excluded signiﬁcant discrepancy between cohorts
from Florence and other centers (14,17).
MUTATIONAL ANALYSIS. After informed consent,
patients were screened for mutations in protein-
coding exons and splice sites of 8 myoﬁlament genes,
including the thin-ﬁlament genes TNNT2, TNNI3,
TPM1, and ACTC; the thick-ﬁlament genes MYBPC3,
MYH7, MYL2; and the essential light chain (MYL3).
Genetic testing using established methods available
at screening was performed by Clinical Laboratory
Improvement Amendments (CLIA)–certiﬁed labora-
tories in the United States and at the Genetics
Unit of Careggi University Hospital in Florence (2).
Direct Sanger sequencing conﬁrmed every variant.
Variants were considered pathogenic if published as
causative HCM mutations in at least 2 independent
peer-reviewed studies. Novel mutations fulﬁlling
the following internationally recommended criteria
were considered likely to be pathogenic (18): 1) non-
synonymous variant causing an amino acid change
TABLE 1 Baseline Clinical Features
Thin Filament
(n ¼ 80)
Thick Filament
(n ¼ 150) p Value
Clinical/demographic features
Female 36 (45) 66 (44) 0.488
Age at enrollment, yrs 44  16 42  17 0.387
Age at ﬁnal evaluation, yrs 49  16 47  17 0.388
Family history of HCM 35 (44) 67 (44) 0.497
Family history of sudden cardiac death 29 (36) 28 (18) 0.004
NYHA functional class
I 53 (66) 92 (61) 0.227
II 21 (26) 43 (29) 0.375
III/IV 6 (8) 16 (10) 0.613
Angina pectoris 16 (20) 30 (20) 0.512
Syncope 14 (18) 21 (14) 0.545
Symptomatic 43 (54) 75 (50) 0.588
Atrial ﬁbrillation 25 (31) 49 (30) 0.827
Abnormal BP response to exercise 19 (24) 19 (13) 0.037
Nonsustained ventricular tachycardia 24 (30) 26 (17) 0.032
Sustained ventricular tachycardia 6 (8) 8 (5) 0.395
ECG
T-wave inversion 54 (67) 66 (44) 0.002
Increased voltage (LV hypertrophy) 48 (60) 97 (65) 0.514
Inferolateral Q waves 30 (37) 14 (9) <0.001
LV strain/repolarization abnormalities 37 (46) 51 (34) 0.087
Echocardiography
Left atrial diameter, mm 44  8 43  8 0.367
Maximum LV wall thickness, mm 18  5 24  6 <0.001
With LV wall thickness >30 mm 6 (7) 26 (17) 0.028
Maximal thickness site
Septum 55 (69) 141 (94) <0.001
Apex 16 (20) 7 (5) <0.001
Concentric 9 (11) 2 (1) <0.001
LV end-diastolic diameter, mm 44  7 45  7 0.303
LV end-systolic diameter, mm 28  7 27  8 0.347
LV ejection fraction, % 65  10 68  12 0.057
With LV ejection fraction <50% 4 (5) 8 (5) 0.420
LVOT gradient, mm Hg 15  24 24  24 0.007
LVOT obstruction 15 (19) 51 (34) 0.015
Moderate-to-severe mitral regurgitation 5 (6) 13 (9) 0.309
LV ﬁlling pattern
Normal 24 (32) 44 (35) 0.459
Impaired relaxation 26 (35) 43 (25) 0.176
Pseudonormalized 18 (25) 35 (28) 0.380
Restrictive 6 (8) 3 (2) 0.064
Triphasic LV ﬁlling 21 (26) 14 (11) 0.002
Lateral E0, cm/s 8.1  3.3 10.6  3.6 <0.001
Cardiac magnetic resonance
Study performed 47 (59) 76 (51) 0.268
LV ejection fraction, % 65  11 71  11 0.004
LV mass index, g/m2 87  27 99  38 0.013
LGE present 40 (85) 61 (80) 0.630
LGE extent, % of LV mass 20  11 16  8 0.002
LGE >30% of LV mass 12 (27) 8 (11) 0.042
Values are n (%) or mean  SD.
BP ¼ blood pressure; ECG ¼ electrocardiograph; HCM ¼ hypertrophic cardiomyopathy; LGE ¼ late gadolinium
enhancement; LV ¼ left ventricular; LVOT¼ left ventricular outﬂow tract; NYHA ¼ New York Heart Association.
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2591in a residue highly conserved among species and pre-
dicted to signiﬁcantly damage protein structure or
function (Grantham, SIFT, and Polyphen scores), or
truncating mutation; 2) the variant was absent in
healthy control populations, including ﬁltering for
1000 Genomes Project, National Heart, Lung and Blood
Institute Exome Sequencing Project, and the Single
Nucleotide Polymorphism database with minimal
allelic frequency of <0.05; and 3) cosegregation with
affected family members could be demonstrated for at
least 1 patient. Before patient enrollment, the
attending cardiologist and clinical geneticists evalu-
ated this information on a case-by-case basis to
conﬁrm variant interpretation. Details of mutation
distribution and classiﬁcation in the thin- and thick-
ﬁlament cohorts are found in Online Tables 1 and 2,
respectively. At the beginning of the study, available
published information was used to classify variant
pathogenicity. Recent next-generation sequencing
data led to subsequent downgrading of 3 thin-ﬁlament
variants from likely pathogenic to variants of uncertain
signiﬁcance (TNNT2-Arg278Cys, TNNT2-Asn262Ser,
and TNNI3-Arg162Pro). All remain potential disease-
causing candidates, and there is evidence of Arg278-
Cys cosegregation in our cohort; thus these mutations
were included in the analysis.
To avoid bias related to founder effects, only the ﬁrst
identiﬁed patient carrying each of 2 highly recurrent
mutations (i.e., E258K [Glu258Lys] in MYBPC3 and
R869H [Arg869His] in MYH7 present in 52 and 19 Flor-
ence index patients, respectively) were included (2). Pa-
tients with complex genotypes, including thin-ﬁlament
mutations associated with pathogenic or likely patho-
genicMYBPC3 orMHY7 variants, were excluded.
ECHOCARDIOGRAPHY. Echocardiographic studies were
performed as described (14) using commercially
available instruments. LV ﬁlling patterns were as-
sessed by pulsed-wave Doppler at the mitral tip level,
and combined with tissue-Doppler evaluation of
lateral mitral annulus velocity. We identiﬁed 4 LV
ﬁlling patterns: (1 ¼ normal; 2 ¼ abnormal relaxation;
3 ¼ pseudonormal; 4 ¼ restrictive), deﬁned according
to existing guidelines (19,20). Triphasic LV ﬁlling was
considered present when a velocity peak of at least
0.2 m/s (an L-wave) was seen during diastasis (21),
independent of the overall LV ﬁlling pattern.
CARDIAC MAGNETIC RESONANCE. Cardiac magnetic
resonance (CMR) imaging, including evaluation of
late gadolinium enhancement (LGE), was performed
as described (22) in a subset of patients using com-
mercially available 1.5-T scanners.
FOLLOW-UP AND CLINICAL OUTCOMES. Patients
were followed up at yearly intervals or more often if
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2592clinically indicated, with review of history and
symptoms, physical examination, echocardiographic
examination, and 12-lead electrocardiography (ECG).
If clinically indicated, ambulatory ECG monitoring for
24 to 48 h and CMR were performed. Established risk
factors for SCD were deﬁned as prior cardiac arrest orFIGURE 2 Genetic Basis of Thin-Filament HCM
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2593We documented major clinical outcomes including
cardiovascular death, resuscitated cardiac arrest,
nonfatal stroke, and progression to severe congestive
symptoms (New York Heart Association [NYHA]
functional class III or IV). Advanced LV dysfunction
was deﬁned by echocardiographic detection ofFIGURE 3 Phenotypic Variability in Thin-Filament–Associated HCM
Echocardiographic and cardiomagnetic resonance (CMR) images showing
in patients from the thin-ﬁlament study cohort (patient’s ID number and
R92Q, with classic localization at the interventricular septum (IVS). (B)
associated with TNNT2-DE163. (C) Mild concentric LVH associated with
and severe LA dilation (restrictive evolution) associated with TNNI3-R18
(F) Apical LVH associated with TPM-M281T; *indicates LV apex. (G) Api
Markedly asymmetric LVH involving the anterior and posterior septum an
patient carrying the TNNT2-F110L mutation. (From left) Four-chamber
noncompaction (black arrowheads) in the LV apical and free wall region
olinium enhancement (white arrowheads) in the anterior free wall andsystolic impairment with an ejection fraction <50%
(generally used to identify end-stage HCM [24]) and/
or restrictive LV ﬁlling pattern.
STATISTICAL ANALYSIS. Unpaired Student t tests
were used to compare normally distributed data fromvariable extent and distribution of left ventricular hypertrophy (LVH)
mutation are indicated). (A) Moderate LVH associated with TNNT2-
Mild midseptal hypertrophy and marked left atrial (LA) dilation
TNNT2-R92W. (D) Moderate midseptal LVH with small LV cavity size
6Q. (E) Classic asymmetric septal LVH associated with TNNI3-K183M.
cal LVH with severe LA dilation associated with ACTC-F23L. (H)
d anterior wall associated with TNNT2-R92W. (I) CMR images from a
and midventricular short-axis views showing extensive regions of
s; 4-chamber and short-axis views showing large areas of late gad-
in the septum, respectively. HCM ¼ hypertrophic cardiomyopathy.
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2594patients with thick- and thin-ﬁlament HCM. Chi-
square or Fisher exact tests were used to compare
noncontinuous variables expressed as proportions.
Survival curves were constructed according to the
Kaplan-Meier method, and comparisons were per-
formed using the log-rank test. Cox proportional
hazard models were used to assess the effects of
multiple clinical features on the risk of outcome
events and to estimate survival curves of thin- versus
thick-ﬁlament patients at net of covariates. Time of
ﬁrst clinical evaluation at each institution was
considered as time 0. The probability values are
2-sided and considered signiﬁcant when <0.05. Cal-
culations were performed using SPSS version 20.0
software (SPSS, Chicago, Illinois).
RESULTS
GENETIC PROFILE OF THIN-FILAMENT HCM. A total
of 39 different pathogenic or likely pathogenic
sequence variants were identiﬁed in 80 unrelated
probands with thin-ﬁlament HCM (Figure 2, Online
Table 1), including 35 missense, 2 truncation, and 2
insertion/deletion mutations. TNNT2 defects were
the most common, with 15 distinct mutations identi-
ﬁed in 43 of the 80 patients (53%). Additionally, we
identiﬁed 15 different TNNI3 mutations in 24 patientsic LV Filling Pattern
mitral blood ﬂow velocity patterns assessed by pulsed-wave Doppler
9 patients with thin-ﬁlament–associated hypertrophic cardiomyopa-
ers and mutations are shown). Mid-diastolic ﬂow velocity (L-wave) is
L wave’s presence is independent of the overall diastolic pattern, with
e <1 (i.e., delayed relaxation) or >1 (i.e., pseudonormalized). LV ¼ left(30%), 5 TPM1 mutations in 7 patients (9%), and 4
ACTC mutations in 6 patients (8%). None carried
double thin-ﬁlament mutations. Patients carrying
mutations in the most represented genes, TNNT2 and
TNNI3, showed remarkably similar clinical features
and outcome proﬁles (Online Tables 3 and 4). Among
the 150 thick-ﬁlament HCM patients enrolled for
comparison (age 42  17 years, 44% female), 94
different mutations were identiﬁed (Online Table 2),
including 49 in MYBPC3 (n ¼ 83, 55%), 40 in MHY7
(n ¼ 57, 38%), and 5 in MYL2 (n ¼ 10, 7%).
BASELINE CLINICAL CHARACTERISTICS OF THIN- VERSUS
THICK-FILAMENT HCM. Cl in i ca l s tatus . At initial
evaluation, the mean age of the 80 thin-ﬁlament HCM
patients was 44  16 years; 45% were women. Most
(66%) reported normal exercise tolerance (NYHA
functional class I); however, 54%were symptomatic as
a result of atrialﬁbrillation (AF) (30%), angina (20%), or
syncope (18%) (Table 1). Overall, these features were
comparable to the thick-ﬁlament cohort (Table 1). On
12-lead ECG, 37% of thin-ﬁlament patients showed
inferolateral Q waves (vs. 9% in the 150 thick-ﬁlament
patients, p < 0.001) and 67% showed inverted T waves
in the precordial leads (vs. 44% of thick-ﬁlament pa-
tients, p ¼ 0.002) (Table 1).
Card iac imaging . Several differences between thick-
and thin-ﬁlament HCM in LVmorphology and function
were noted. Patients with thin-ﬁlament mutations
had lesser maximal LV wall thickness values than
the thick-ﬁlament group (18  5 mm vs. 24  6 mm;
p < 0.001) and more often exhibited atypically
distributed hypertrophy (31%), including concentric
and apical patterns, whereas 94% of thick-ﬁlament
HCM presented as classic asymmetric LVH involving
the basal septum and anterior wall (p < 0.01) (Table 1,
Figure 3), consistent with the lower prevalence of
resting LV outﬂow tract obstruction in thin-ﬁlament
patients (19% vs. 34% in thick-ﬁlament HCM, p ¼ 0.015).
An apical or concentric distribution of hypertrophy
was most likely in TNNI3 patients (41%) (Online
Table 3). Aspects of LV noncompaction were uncom-
mon; for example, none of the 6 patients with actin
mutations showed regional noncompaction.
Transmitral pulsed-wave interrogation showed
a triphasic LV ﬁlling pattern characterized by an
L-wave with prominent mid-diastolic ﬂow velocity in
26% of thin-ﬁlament patients, but in only 11% with
thick-ﬁlament disease (p ¼ 0.002) (Figure 4). Fur-
thermore, early diastolic lateral mitral annulus veloc-
ity (E0) was 24% lower in patients with thin compared
with thick-ﬁlament mutations (p < 0.001) (Table 1).
CMR studies in 47 thin-ﬁlament patients (59%)
and 76 thick-ﬁlament patients (51%) highlighted
signiﬁcant differences between these cohorts.
TABLE 2 Management and Clinical Outcomes
Thin Filament
(n ¼ 80)
Thick Filament
(n ¼ 150) p Value
Follow-up, yrs 4.7  2.7 4.7  3.0 0.492
Clinical outcomes
HCM-related death 2 (2) 10 (6) 0.167
Heart failure related 1 (1) 1 (1) 0.321
Sudden-unexpected 1 (1) 9 (7) 0.091
Resuscitated cardiac arrest 4 (5) 3 (2) 0.241
Appropriate ICD shocks 6 (8) 5 (3) 0.158
Total with malignant arrhythmias* 11 (14) 17 (11) 0.593
Nonfatal stroke 3 (4) 6 (4) 0.542
NYHA functional class at ﬁnal evaluation
I 41 (51) 79 (53) 0.267
II 24 (30) 56 (37) 0.750
III/IV 16 (20) 15 (10) 0.034
Progression to NYHA functional class III or IV 12 (15) 8 (5) 0.013
New-onset AF 9 (11) 14 (9) 0.527
Final echocardiographic evaluation
LVEF, % 60  10 63  11 0.043
With LVEF <50% 14 (18) 12 (8) 0.031
LV ﬁlling pattern
Normal 17 (21) 32 (26) 0.406
Impaired relaxation 19 (24) 45 (36) 0.113
Pseudonormalized 27 (34) 41 (33) 0.362
Restrictive 13 (16) 7 (5) 0.003
With progression to EF <50%/restrictive diastole 16 (20) 14 (9) 0.038
Moderate/severe left atrial dilation† 40 (50) 51 (34) 0.023
Interventions
Implantable cardioverter-deﬁbrillator 19 (24) 36 (24) 0.516
Catheter ablation for AF 10 (12) 8 (5) 0.040
Alcohol ablation or myectomy 11 (14) 38 (25) 0.041
Pharmacological therapy
On treatment 75 (94) 141 (94) 0.503
Beta-blockers 54 (67) 113 (75) 0.411
Verapamil 20 (25) 8 (5) <0.001
Amiodarone 14 (18) 29 (19) 0.383
Disopyramide 2 (3) 34 (23) <0.001
Diuretics 22 (27) 23 (15) 0.038
ACE inhibitors or ARB 27 (34) 31 (21) 0.033
Warfarin 17 (21) 21 (14) 0.102
Values are mean  SD or n (%). *Including sudden cardiac death, resuscitated cardiac arrest, and appropriate ICD
shocks. †Left atrial diameter >45 mm in men or >42 mm in women.
ACE ¼ angiotensin-converting enzyme; AF ¼ atrial ﬁbrillation; ARB ¼ angiotensin receptor blockers; EF ¼
ejection fraction; LVEF ¼ left ventricular ejection fraction; ICD ¼ implantable cardioverter-deﬁbrillator; other
abbreviations as in Table 1.
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2595Thin-ﬁlament patients had a smaller LV mass index
and a lower LV ejection fraction (Table 1). Although
LGE was present in the majority of patients from both
cohorts, the proportion of LV mass occupied was
larger in thin-ﬁlament patients (20  11% vs. 16  8%
in thick-ﬁlament patients). LGE exceeded 30% of
LV mass in 12 thin-ﬁlament patients (27%), 10 of
whom showed an EF <50% or a restrictive diastolic
pattern at ﬁnal evaluation. Only 8 thick-ﬁlament pa-
tients (11%) showed LGE exceeding 30% of the LV.
SCD r i sk proﬁ le . Compared with the thick-ﬁlament
cohort, thin-ﬁlament patients had a higher preva-
lence of NSVT, abnormal blood pressure response to
exercise, and family history of SCD and were more
likely to have at least 1 established SCD risk factor (74%
vs. 59%; p ¼ 0.031) (Table 1). However, the proportion
of patients with 2 or more risk factors was similar in
both groups (30% vs. 34%, respectively, p ¼ 0.39).
CLINICAL OUTCOMES AND SYMPTOMATIC PROGRESSION.
Mean follow-up for the thin-ﬁlament cohort was 4.7
 2.7 years, for a total of 361 patient-years, compa-
rable to the thick-ﬁlament group (4.7  3.0 years,
p ¼ 0.49). During this time, 2 patients from the
thin-ﬁlament cohort (2.5%) died of cardiac causes
(1 suddenly, 1 because of heart failure), 3 (4%)
experienced nonfatal strokes, 3 (4%) had resusci-
tated cardiac arrests, and 5 (6%) had appropriate
implantable cardioverter-deﬁbrillator (ICD) shocks
owing to rapid ventricular tachycardia or ﬁbrillation
(Table 2). All-cause mortality, cardiac mortality,
and SCD rates did not differ between the cohorts
(p > 0.05 for all comparisons) (Table 2), and their
rates of malignant arrhythmias (including sudden
death, resuscitated cardiac arrest, and appropriate
ICD shocks) were also similar (Table 2).
At ﬁnal evaluation, moderate or severe congestive
symptoms (NYHA functional class III/IV) were more
prevalent in the thin comparedwith the thick-ﬁlament
subgroup (19%vs. 10%; p¼0.034) (Table 2). Notably, 12
(15%) thin-ﬁlament patients with mild or no symp-
toms at initial evaluation progressed to NYHA func-
tional class III/IV during follow-up at a mean age of
50  9 years, 3 times the prevalence in the thick-
ﬁlament cohort (5%; p ¼ 0.013). Survival analysis
showed a higher likelihood of developing moderate
or severe congestive symptoms among thin-ﬁlament
patients (Figure 5A). At multivariate analysis, per-
formed on the 2 HCM cohorts combined, the pres-
ence of thin-ﬁlament disease more than doubled the
likelihood of a ﬁnal NYHA functional class III/IV
(hazard ratio [HR]: 2.16, p ¼ 0.040), independent of
LV outﬂow obstruction (HR: 4.06; p <0.001) and AF
(HR 2.74, p ¼ 0.008) (Online Figure 1).EVIDENCE OF ADVERSE LV REMODELING AND
DYSFUNCTION. Advanced LV dysfunction (deﬁned as
LVEF <50% or restrictive diastolic pattern) was pre-
sent at ﬁnal evaluation in 23 of the 80 thin-ﬁlament
patients (29%) at ages ranging from 20 to 76 years,
compared with 17 of the 150 thick-ﬁlament patients
(p ¼ 0.002). Of note, 10 of these 23 patients (43%) were
younger than 50 years of age (Figure 6). The incidence
of new LV dysfunction during follow-up proved higher
in the thin-ﬁlament cohort (4.3% per annum) than in
FIGURE 5 Clinical and Instrumental Outcomes in Thick- Versus Thin-Filament HCM
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(A) Kaplan-Mayer curve illustrating survival free of progression to severe heart failure
(New York Health Association [NYHA] functional classes III/IV). (B) Survival free of
adverse left ventricular (LV) remodeling and dysfunction during follow-up, deﬁned as
progression to LV ejection fraction (EF) <50% or toward restrictive LV ﬁlling pattern.
(C) Lifelong likelihood of advanced LV dysfunction (deﬁned as in B) in relation to
genetic status. The probability values are calculated with the log-rank test comparing
thin-ﬁlament versus thick-ﬁlament survival curves. HCM ¼ hypertrophic cardiomyo-
pathy; NYHA ¼ New York Heart Association.
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(Figures 5B and 5C). In multivariate analysis, thin-
ﬁlament mutations predicted LV dysfunction (HR:
2.28, p ¼ 0.016) independent of female sex (HR: 2.08,
p ¼ 0.031), AF (HR: 2.33, p ¼ 0.023), and NYHA func-
tional class III symptoms at baseline (HR: 2.64,
p ¼ 0.044) (Online Figures 2 and 3). Consistent with
the pronounced diastolic impairment, thin-ﬁlament
patients more often had moderate or severe atrial
dilation at ﬁnal evaluation than thick-ﬁlament
patients. Conversely, the incidence of new AF during
follow-up was comparable in both groups (Table 2).
MANAGEMENT. During follow-up, most thin-ﬁlament
patients (n ¼ 75; 94%) received pharmacological
treatment for HCM, including beta-blockers, verap-
amil, amiodarone, and disopyramide (Table 2). Pre-
dictably, they were more frequently treated with
diuretics and angiotensin-converting enzyme in-
hibitors or angiotensin receptor blockers than the
thick-ﬁlament cohort but less often received dis-
opyramide (Table 2).
Nineteen thin-ﬁlament patients (24%) received an
ICD (Table 2), including 16 for primary and 3 for sec-
ondary prevention of SCD. Furthermore, 11 patients
(14%) were referred for surgical septal myectomy
(n ¼ 7) or alcohol septal ablation (n ¼ 4) for drug-
refractory symptoms associated with LV outﬂow tract
obstruction. Finally, 11 patients (14%) underwent
radiofrequency catheter ablation for symptomatic,
drug-refractory AF. Compared with thick-ﬁlament
patients (Table 2), thin-ﬁlament patients more often
underwent catheter ablation procedures for AF but
were less frequently referred for invasive septal
reduction therapies; ICD implantation rates were
comparable (Table 2).
DISCUSSION
This study supports the hypothesis that thin-ﬁlament
HCM is phenotypically distinct from the more com-
mon thick-ﬁlament HCM (4,6,9,12). Speciﬁc LV
morphological, functional, and remodeling differ-
ences were identiﬁed, suggesting unique underlying
pathophysiological mechanisms (4,6). At initial eval-
uation, thin-ﬁlament patients showed lesser LV hy-
pertrophy, often developing in apical or concentric
patterns, whereas patients with thick-ﬁlament dis-
ease almost universally displayed classic asymmetric
LV hypertrophy involving the basal septum and
anterior wall (25). As a result, dynamic LV outﬂow
tract obstructionwas less common in the thin-ﬁlament
cohort (19%, compared with 34% among thick-
ﬁlament patients, p ¼ 0.015) (15), likely as a result
of relative preservation of LV outﬂow morphology
FIGURE 6 Evidence of Disease Progression in Thin-ﬁlament HCM
(A) Echocardiographic images from patient ID #5 carrying the TNNT2-F110L mutation. Top:
Echocardiographic evaluation at age 16 years. (Left) Parasternal short-axis view showing
severe and diffuse anteroseptal LV hypertrophy. (Right) Parasternal long-axis view
showing turbulent ﬂow in the LV outﬂow tract (arrow), caused by severe dynamic
obstruction. (Bottom) Similar views from the same patient at age 37 years, showing
marked anteroseptal wall thinning and absence of obstruction and increased left atrial size.
(B) CMR images from patient ID #32 carrying the TNNT2-R92W mutation. (Top) Cardiac
magnetic resonance at age 21 years. Short-axis and 3-chamber views show absence of late
gadolinium enhancement (LGE) in the LV wall. (Bottom) Similar views from the same
patient at age 25 years. LGE shows extensive ﬁbrous substitution within the anterior
septum (arrow), occupying 25% of total LV mass. Abbreviations as in Figure 5.
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anterior motion (14). Conversely, diastolic abnor-
malities were more common and pronounced in
thin-ﬁlament HCM, including 16% of patients with
restrictive LV pathophysiology.More than one-quarter
of our thin-ﬁlament patients exhibited a triphasic LV
ﬁlling pattern, compared with only 11% in the thick-
ﬁlament subgroup, a disproportionate prevalence,
consistent with severe diastolic impairment (21,26).
The presence of an L wave (a velocity peak $0.2 m/s
during diastasis) (21), believed to indicate elevated
ﬁlling pressures (27) and previously observed in
HCM (28), has been associated with extensive sep-
tal ﬁbrosis (26). Indeed, substantial LV remodeling
occurred in thin-ﬁlament patients, mediated by pro-
gressive myocardial ﬁbrosis (Figure 6). LGE was pre-
sent in 85% of patients undergoing CMR and averaged
20% of the whole LV, reﬂecting greater prevalence
and extension of ﬁbrous tissue compared with our
thick-ﬁlament patients and previously published,
unselected HCM cohorts, largely reﬂecting thick-
ﬁlament disease (29,30).
LV DYSFUNCTION AND HEART FAILURE IN
THIN-FILAMENT HCM. At the end of 4.7 years of
follow-up, 29% of the 80 thin-ﬁlament patients had
advanced LV dysfunction (deﬁned as LVEF <50% or
restrictive diastolic pattern), more than double the
prevalence among thick-ﬁlament patients. Indeed,
the incidence of newly occurring systolic dysfunction
in our thin-ﬁlament patients was approximately 2.5%
per year, compared with approximately 1% per year in
our thick-ﬁlament subset; the latter value closely
agrees with values in unselected HCM populations
(31,32). Furthermore, restrictive LV pathophysiology
with preserved systolic function was observed in 11%
of thin-ﬁlament patients during follow-up, consistent
with prior reports emphasizing isolated, severe dia-
stolic dysfunction in patients with troponin muta-
tions, particularly troponin I, which occasionally
presents as primary restrictive disease (33).
At ﬁnal evaluation, the adverse remodeling process
observed in thin-ﬁlament HCM patients was paral-
leled by a considerable prevalence of moderate or
severe congestive symptoms. Overall, 15% of thin-
ﬁlament patients initially presenting with mild or no
symptoms progressed to NYHA functional class III/IV
during follow-up, 3 times the prevalence in the thick-
ﬁlament cohort (5%; p ¼ 0.013). In a multivariate
model assessing established predictors of HCM
outcome, thin-ﬁlament disease more than doubled
the likelihood of a ﬁnal NYHA functional class III/IV,
independent of LV outﬂow obstruction and AF.
Conversely, thick- and thin-ﬁlament HCM patients
had comparably low rates of malignant ventricular
CENTRAL ILLUSTRATION Morphological and Functional Features and Outcomes of HCM Owing to
Thin-Filament Mutations
(Top) Hearts with thin-ﬁlament (left, blue/gray) and thick-ﬁlament (right, light blue/gray) mutations, highlighting the main morphological
and functional features of the 2 groups (1 arrow ¼ a poorly represented feature, 2 arrows ¼ a moderately represented feature, and 3 arrows ¼
a highly prevalent feature). (Bottom) Outcome of thin-ﬁlament and thick-ﬁlament HCM. Adverse remodeling is more common in thin-ﬁlament
patients and may lead to either restrictive or hypokinetic morphological and functional end-stage phenotypes. Both are more represented in
thin-ﬁlament patients and are related to increased prevalence of heart failure symptoms in the thin-ﬁlament cohort. HCM ¼ hypertrophic
cardiomyopathy; LV ¼ left ventricular.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: HCM associated
with thin-ﬁlament mutations is characterized by less prominent
and atypically distributed hypertrophy; increased ﬁbrosis; and
more adverse remodeling (hypokinetic or restrictive evolution),
leading to congestive symptoms, triphasic left ventricular ﬁlling,
and more severe diastolic dysfunction, compared with thick-
ﬁlament HCM.
COMPETENCY IN PATIENT CARE: Aggressive measures for
primary prevention of sudden death with implanted cardiac de-
ﬁbrillators in patients with HCM should not be based solely on
genotype.
TRANSLATIONAL OUTLOOK 1: Better understanding of early
phenotype development in thin-ﬁlament cardiomyopathy will
require studies of index patients’ families, including monitoring
of young relatives carrying thin-ﬁlament mutations over a rela-
tively long period and comparison with carriers of thick-ﬁlament
mutations.
TRANSLATIONAL OUTLOOK 2: Preclinical studies involving
transgenic animal models are warranted to assess mechanisms of
disease progression and to test pharmacological strategies for
controlling symptoms and reducing adverse myocardial remod-
eling in thin-ﬁlament HCM.
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2599arrhythmias, including SCD, resuscitated cardiac ar-
rest, and appropriate ICD interventions. This limited
arrhythmic propensity contrasts with prior reports
suggesting increased risk of SCD in patients with
troponin T or I mutations, likely because of the ma-
lignant proﬁle of the highly selected families in early
studies (8). Although individual arrhythmic risk may
vary considerably, particularly in children and ado-
lescents, thin-ﬁlament HCM in our cohort emerged as
a progressive condition characterized by adverse LV
remodeling and dysfunction, rather than by en-
hanced arrhythmogenicity. Clinical implications
include the need for heightened attention to early
signs of LV dysfunction and symptom progression
in patients with thin-ﬁlament HCM. Conversely,
aggressive strategies for primary prevention of SCD,
including ICDs, are not warranted solely because a
thin-ﬁlament mutation is present (13,23).
MOLECULAR CONSEQUENCES OF THIN-FILAMENT
MUTATIONS. Preclinical studies using animal models
support key features identiﬁed in our cohort of patients
with thin-ﬁlament HCM (4). Transgenic mouse lines
with thin-ﬁlament gene defects develop restrictive
diastolic patterns and systolic dysfunction over time
(34). Skinned myocardial tissue from patient samples
and animal models with thin-ﬁlament mutations
consistently show markedly increased myoﬁlament
Ca2þ sensitivity (35), closely related to abnormalities of
cardiac relaxation (36) and diastolic dysfunction.
Furthermore, thin-ﬁlament defects can alter cardiac
function by increasing the energy cost of contraction
(37). Although several of these abnormalities are
shared with defects in other HCM-related genes, their
extent is generally greater in thin-ﬁlament HCM
samples. The constellation of early impairment in
excitation-contraction coupling, energetic derange-
ment, abnormal cardiomyocyte signaling, and intrinsic
abnormalities of sarcomeric relaxation caused by thin-
ﬁlament mutations may collectively drive aggressive
remodeling at the cellular and extracellular levels (6),
resulting in impaired contractile and relaxation
properties of the myocardium (6,38); these ultimately
account for the common occurrence of progressive
LV dysfunction observed in our HCM cohort.
CONCLUSIONS
Distinctive clinical and biophysical features charac-
terize HCM associated with thin-ﬁlament mutations,at variance with the more common thick-ﬁlament
disease. Thin-ﬁlament HCM is associated with less
prominent and atypically distributed LV hypertrophy,
increased LV ﬁbrosis, higher likelihood of adverse
LV remodeling leading to functional deterioration,
and more frequent occurrence of triphasic LV ﬁlling,
reﬂecting profound diastolic dysfunction (Central
Illustration). Management strategies should consider
adequate surveillance for early detection of LV dys-
function and symptomatic progression. Conversely,
arrhythmic risk does not appear to increase solely as
a result of a thin-ﬁlament genotype.
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